Year: 2026
Type: preprint
Abstract: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by immune tolerance loss, although its pathogenesis remains incompletely understood. Immune checkpoint molecules maintain peripheral tolerance, and their dysregulation contributes to autoimmunity. Autoantibodies against lymphocyte activation gene-3 (LAG-3), an immune checkpoint molecule, were identified in a subset of patients with SLE. We enrolled 130 patients with SLE, 119 patients with other autoimmune diseases, and 32 healthy controls. The sera of patients with SLE were screened for antibodies against various immune checkpoint molecules to identify clinically relevant disease-specific autoantibodies against LAG-3. Functional assays were performed to assess the effect of anti-LAG-3 autoantibodies on the interaction between LAG-3 and major histocompatibility complex (MHC) class II. Pathogenic relevance was evaluated using genetic deletion and immunization-based mouse models. Anti-LAG-3 autoantibodies were detected in 52/130 patients with SLE (40.0%) but only 4 of 119 patients with other autoimmune diseases (3.4%). These autoantibodies were associated with lupus nephritis and higher disease activity. In mice, Lag3 deletion or human LAG-3 immunization induced lupus-like autoimmunity. These findings support the clinical relevance of anti-LAG-3 autoantibodies in SLE and implicate LAG-3 checkpoint disruption in lupus-like autoimmunity.
Authors: Yuya Muramoto, Masahiro Shiokawa, Yukako Maeda, Takeshi Kuwada, Yoshihiro Nishikawa, Tatsuaki Tsuruyama, Takahisa Maruno, Takafumi Yanaidani, Kenji Sawada, Ayako Hirata, Koki Chikugo, Masataka Yokode, Shimpei Matsumoto, Sakiko Ota, Tomoaki Matsumori, Kazushi Izawa, Eitaro Hiejima, Keiji Akamine, Mao Mizuta, Hiroyuki Yoshida, Masaaki Fujita, Ran Nakashima, Hajime Yoshifuji, Tsutomu Chiba, Junko Takita, Akio Morinobu, Hiroshi Seno
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7237345590
